Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Penserra Capital Management LLC

Posted by on Feb 28th, 2023

Penserra Capital Management LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 537.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102 shares of the biopharmaceutical company’s stock after buying an additional 86 shares during the period. Penserra Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $70,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in REGN. Ronald Blue Trust Inc. increased its position in Regeneron Pharmaceuticals by 157.9% in the third quarter. Ronald Blue Trust Inc. now owns 49 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 30 shares during the period. SeaCrest Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $40,000. Eagle Bay Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $60,000. Castleview Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5,459.3% during the second quarter. Castleview Partners LLC now owns 3,280 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 3,221 shares during the period. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Regeneron Pharmaceuticals by 36.4% during the third quarter. Parkside Financial Bank & Trust now owns 105 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 28 shares during the period. 84.25% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.1 %

NASDAQ:REGN opened at $757.79 on Tuesday. The stock has a fifty day simple moving average of $736.78 and a 200 day simple moving average of $716.13. The firm has a market capitalization of $82.85 billion, a price-to-earnings ratio of 19.82, a price-to-earnings-growth ratio of 2.60 and a beta of 0.25. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $538.01 and a 1-year high of $800.48.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last announced its quarterly earnings data on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.18 by $4.38. The firm had revenue of $3.41 billion during the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a return on equity of 22.87% and a net margin of 35.64%. The business’s revenue for the quarter was down 31.1% on a year-over-year basis. During the same period in the prior year, the business earned $23.72 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 218 shares of the stock in a transaction dated Thursday, December 8th. The stock was sold at an average price of $779.00, for a total value of $169,822.00. Following the completion of the sale, the director now directly owns 1,082 shares of the company’s stock, valued at approximately $842,878. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Bonnie L. Bassler sold 218 shares of the firm’s stock in a transaction dated Thursday, December 8th. The stock was sold at an average price of $779.00, for a total transaction of $169,822.00. Following the completion of the sale, the director now directly owns 1,082 shares of the company’s stock, valued at approximately $842,878. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 264 shares of the firm’s stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $730.17, for a total value of $192,764.88. Following the sale, the executive vice president now directly owns 19,106 shares of the company’s stock, valued at $13,950,628.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,555 shares of company stock valued at $20,640,437. Corporate insiders own 8.99% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. Truist Financial raised their price target on Regeneron Pharmaceuticals from $790.00 to $856.00 in a report on Wednesday, November 9th. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $853.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. raised Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 price target on the stock in a report on Friday, January 20th. StockNews.com raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 23rd. Finally, Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $789.00 to $787.00 and set a “sector perform” rating for the company in a research note on Monday, February 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $803.19.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.